CLX · Clorox Co /De/
$81.30
-0.30 (-0.37%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$9.85B
Shares
120.92M
Volume · Sep 30
2.76M
Avg daily vol (3M)
2.83M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$81.60
Open$81.19
Day$80.97–81.99
52W close$81.42–127.16
Avg vol 30d3.1M
Short int8.5M · 7.0% float · 2.9d
Short vol64%
Last earningsAug 3, 2026
DataJan 2020–Sep 2026
Filing10-K · Aug 7
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 5 wks
filed Aug 7, 2026
call held Aug 3, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-33.7%
Trailing year
Short interest
7.0%
Latest settlement · 2.9 days to cover
AI Brief
Q4 FY26 earnings call · Aug 3, 2026
Q4 FY26
TL;DR. Clorox delivered FY26 results in line with expectations, with full-year organic sales down 8% and adjusted EPS down 28%, as lapping of ERP-related shipments pressured comparisons. For FY27, the company guided to net sales up 13%-14% and adjusted EPS of $5.70-$6.00, including a benefit from lapping the prior-year ERP inventory drawdown, but expects ~$200M+ in inflation driving gross margin to only ~42%.
Bullish
- + FY27 net sales guided up 13%-14% with organic sales up 3.5%-4.5%, including more than 3.5 points of benefit from lapping the ERP-related inventory drawdown
- + FY27 adjusted EPS guided to $5.70-$6.00, a 3%-8% increase
- + Completed the GOJO acquisition, expanding the health and hygiene platform to over half of net sales
- + Completed the U.S. ERP implementation, concluding the five-year digital transformation investment
- + Innovation as a percent of sales nearly doubled in FY26, with a strong innovation slate planned for FY27
Bearish
- − FY26 gross margin contracted 290 bps to 42.3%, with Q4 down 520 bps to 41.3%
- − FY26 adjusted EPS fell 28% to $5.53 and diluted EPS fell 26% to $4.81
- − FY27 gross margin guided to only ~42% as more-than-doubled inflation above $200M outweighs cost savings and pricing
- − FY26 net cash provided by operations fell 38% to $612M, primarily driven by the Glad Venture Agreement termination payment
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Moderate
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−20%
below
Price vs 50-day avg
−15%
below
RSI (14)
31
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−16%
trailing
6-month return
−23%
trailing
YTD return
−19%
this year
Relative strength
−36%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $96 › 200d $102 — 200d above 50d
Institutional flow
Distributing
-3% holders QoQ · +141 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
7.03% of float · ▼ -20.4% MoM · 2.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1,063 holders — near 3-yr low, contrarian setup
Squeeze score
50
elevated · 0–100
Fundamentals
Revenue growth
+3%
Y/Y
Gross margin
52%
expanding
EPS growth
+190%
Y/Y
Free cash flow
$761.0M
Buyback
$2.0B
authorized
Balance sheet
$2.3B
net debt
Quant / Vol
risk profile
Volatility
32%
annualized · 1-yr
Max drawdown
−36%
past year
ATR
3.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 3, 2026
Net sales
· fiscal year 2027
Initiated
13% – 14%
Gross margin
· fiscal year 2027
Initiated
42%
Selling and administrative expenses
· fiscal year 2027
Initiated
16%
Advertising and sales promotion spending
· fiscal year 2027
Initiated
10%
Effective tax rate
· fiscal year 2027
Initiated
23%
Diluted EPS
· fiscal year 2027
Initiated
$5.41 – $5.71
Adjusted EPS
· fiscal year 2027
Initiated
$5.70 – $6.00
Guided vs delivered
· last 4 settled
Diluted EPS
Fiscal Year 2025
guided $4.95 – $5.20
$6.52
Beat +28.5%
Diluted EPS
Fiscal Year 2024
guided $1.66 – $1.81
$2.25
Beat +29.7%
Diluted EPS
fiscal year 2021
guided $8.05 – $8.25
$5.58
Miss −31.5%
Fiscal year 2020 diluted EPS
fiscal year 2020
guided $6.70 – $6.90
$7.36
Beat +8.2%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−20%
Bearish
Price vs 50-day avg
−15%
Bearish
RSI (14)
31
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $96 › 200d $102 — 200d above 50d
Institutional flow
Distributing
-3% holders QoQ · +141 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
7.03% of float · ▼ -20.4% MoM · 2.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1,063 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $81
Now $82 · 0%
Range high $127
vs 200-day avg -20%
vs 50-day avg -15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted after tax profit attributable to Clorox non-GAAP | $775M | FY26 filing | — |
| Adjusted free cash flow non-GAAP | $881M | fiscal year 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by operations 612M
-207M Capital expenditures
+476M Venture agreement termination payment
= Adjusted free cash flow 881M
|
|||
| Adjusted free cash flow as a percentage of net sales non-GAAP | 13.1% | fiscal year 2026 filing | — |
| Average capital employed non-GAAP | $4.2B | FY26 filing | — |
| Bags and wraps (as a percentage of consolidated net sales) | 15% | fiscal year ended June 30, 2026 filing | — |
| Capital charge non-GAAP | $378M | FY26 filing | — |
| Capital expenditures as a percentage of net sales | 3.1% | fiscal year 2026 filing | — |
| Cat litter products (as a percentage of consolidated net sales) | 10% | fiscal year ended June 30, 2026 filing | — |
| Cleaning products (as a percentage of consolidated net sales) | 44% | fiscal year ended June 30, 2026 filing | — |
| Dividends paid to shareholders | 602M | fiscal year 2026 filing | — |
| Economic profit non-GAAP | $397M | fiscal year 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Earnings before income taxes 791M
+117M Certain U.S. GAAP items
+130M Interest expense
-249M Income taxes on earnings before income taxes, certain U.S. GAAP items and interest expense
-14M After tax profit attributable to noncontrolling interests
-378M Capital charge
= Economic profit 397M
|
|||
| Employees worldwide | 9,200 | fiscal year 2026 filing | — |
| Food products (as a percentage of consolidated net sales) | 11% | fiscal year ended June 30, 2026 filing | — |
| Number of countries or territories of operations | 25 | fiscal year 2026 filing | — |
| Number of markets where products are sold | 95 | fiscal year 2026 filing | — |
| Organic sales growth / (decrease) non-GAAP | -8% | fiscal year 2026 filing | — |
| Percent of net sales attributable to U.S. markets | 84% | fiscal year 2026 filing | — |
| Recordable incident rate (RIR) | 0.63 | fiscal year 2026 filing | — |
| Share of sales from brands holding No. 1 or No. 2 market share positions | 80% | fiscal year 2026 filing | — |
| Total incremental transformational investment | 580M | fiscal year 2026 filing | — |
| U.S. retail advertising investments as a percentage of net sales | 12% | fiscal year 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Household & Personal Products — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLX
this stock
Clorox Co /De/
|
$9.85B | -19.1% | +2.5% | — | 7.0% |
|
PG
PROCTER & GAMBLE Co
|
$339.90B | +3.5% | +3.3% | 22.1 | 1.0% |
|
UL
Unilever PLC
|
$134.67B | -6.4% | — | — | 0.2% |
|
CL
Colgate Palmolive Co
|
$69.13B | +9.4% | +1.7% | 34.3 | 2.3% |
|
RBGLY
Reckitt Benckiser Group PLC
|
$41.79B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLX | -6.4% | -16.5% | -22.8% | -16.5% | -19.1% |
| SPY | -1.2% | -0.4% | +13.1% | -0.4% | +12.1% |
| vs SPY | -5.2% | -16.1% | -35.8% | -16.1% | -31.1% |
Capital returns
Declared · upcoming
$1.25
/ share · ex Oct 28, 2026
Paid (TTM)
$0.00
/ share · 0 payouts
Dividend yield (TTM, derived)
— · no payout in the trailing year
Buyback program
· as of Mar 31, 2021
Authorized
$2.00B
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.